13.12.2021 • Newscabot

Cabot and IFF Link on Rubber Additives

Cabot has signed a Memorandum of Understanding (MoU) with IFF Health and Biosciences to develop and commercialize sustainable reinforcing additives for rubber products. Under the agreement, the companies will exclusively work together to accelerate innovative technologies that reduce greenhouse gas emissions and increase the amount of renewable bio-based content

“We are proud to collaborate with IFF to test and develop renewable bio-based additives as a complement to reinforcing carbons in rubber products for applications, including tires, belts, hoses, gaskets and automotive weatherstrips. This MOU aligns with our sustainability commitment and contributes to the transition to a lower carbon future.” said Fred Rumpf, Cabot’s senior R&D director, Reinforcement Materials segment.

During the past year, Cabot and IFF have been exploring the development of novel, highly sustainable rubber reinforcing additives based on the latter’s Nuvolve engineered polysaccharide.

Nuvolve is produced by the enzymatic polymerization of sustainable European sugar beets. The polysaccharide was originally developed by DuPont, which merged its nutrition and biosciences business into IFF on Feb. 1.  

Author: Elaine Burridge, Freelance Journalist

(c) Cabot
(c) Cabot

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.